PMV Pharmaceuticals is rated Buy, targeting $3–$4/share, driven by Rezatapopt's 46% response rate. Click to read more about the PMVP stock.

PMV Pharmaceuticals PMVP has gained nearly 19% in the past three months, primarily due to encouraging clinical data for its ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

PMV Pharma ended the second quarter with $212.9 million in cash, cash equivalents, and marketable securities, compared to $213.1 million as of March 31, 2024. Net cash used in operations was $17.8 ...

The tumor-suppressing protein p53 has long been considered a valuable target—if only drug hunters could figure out how to hit it. Many research efforts aiming to leverage the capabilities of this ...

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) on Wednesday released interim data from the Phase 2 pivotal portion of the PYNNACLE clinical trial evaluating rezatapopt in patients with advanced solid tumors ...

Matthew Joseph Eckler filed a Form 3 Initial Statement of Beneficial Ownership following his appointment as a Director of PMV ...

PMV Electric says that their first car will get a digital infotainment system and a USB charging port(PMV) 0 PMV, a Mumbai based electric vehicle manufacturer, is all set to launch its micro-electric ...

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States ...